GSK announces EMA accepted for review MAA for depemokimab
Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...
GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...
The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...
GSK plc and the University of Oxford (Oxford) announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer ...
Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...
GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback